Company intelligence / Profile preview
Chongqing Bovax Biopharmaceutical
Chongqing, Chongqing, Chinabovax.com.cn ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Chongqing Bovax is a leading Chinese biotechnology company specializing in recombinant vaccines. Its lead candidate is a 9-valent HPV vaccine currently in Phase 3 clinical trials, positioned to be one of the first domestically produced alternatives to Gardasil 9 in the Chinese market. The company also has 4-valent and 2-valent HPV vaccines in late-stage development.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Chongqing Zhifei Biological Products
Beyond the preview
Go deeper on Chongqing Bovax Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Bovax Biopharmaceutical.